The Company’s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, unvested restricted stock units and common stock options, have been excluded from the computation of diluted net loss per share as the effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:


	As of March 31,
	2022		2021
Convertible preferred stock		—		27,720,923
Unvested restricted stock		—		403,224
Unvested restricted stock units		225,700		—
Outstanding options to purchase common stock		7,536,372		5,188,558
Total		7,762,072		33,312,705

As part of the license agreement with Harvard and Broad, the Company is required to make success payments. The Company may elect to make these payments by issuing shares of the Company's common stock. As of December 31, 2021, an aggregate of $6.3 million was earned relating to these success payments, which the Company settled in cash.